PT  - JOURNAL ARTICLE
AU  - Emmenegger, Marc
AU  - De Cecco, Elena
AU  - Lamparter, David
AU  - Jacquat, Raphaël P. B.
AU  - Ebner, Daniel
AU  - Schneider, Mathias M.
AU  - Morales, Itzel Condado
AU  - Schneider, Dezirae
AU  - Doğançay, Berre
AU  - Guo, Jingjing
AU  - Wiedmer, Anne
AU  - Domange, Julie
AU  - Imeri, Marigona
AU  - Moos, Rita
AU  - Zografou, Chryssa
AU  - Trevisan, Chiara
AU  - Gonzalez-Guerra, Andres
AU  - Carrella, Alessandra
AU  - Dubach, Irina L.
AU  - Althaus, Christian L.
AU  - Xu, Catherine K.
AU  - Meisl, Georg
AU  - Kosmoliaptsis, Vasilis
AU  - Malinauskas, Tomas
AU  - Burgess-Brown, Nicola
AU  - Owens, Ray
AU  - Hatch, Stephanie
AU  - Mongkolsapaya, Juthathip
AU  - Screaton, Gavin R.
AU  - Schubert, Katharina
AU  - Huck, John D.
AU  - Liu, Feimei
AU  - Pojer, Florence
AU  - Lau, Kelvin
AU  - Hacker, David
AU  - Probst-Müller, Elsbeth
AU  - Cervia, Carlo
AU  - Nilsson, Jakob
AU  - Boyman, Onur
AU  - Saleh, Lanja
AU  - Spanaus, Katharina
AU  - von Eckardstein, Arnold
AU  - Schaer, Dominik J.
AU  - Ban, Nenad
AU  - Tsai, Ching-Ju
AU  - Marino, Jacopo
AU  - Schertler, Gebhard F. X.
AU  - Ebert, Nadine
AU  - Thiel, Volker
AU  - Gottschalk, Jochen
AU  - Frey, Beat M.
AU  - Reimann, Regina
AU  - Hornemann, Simone
AU  - Ring, Aaron M.
AU  - Knowles, Tuomas P. J.
AU  - Xenarios, Ioannis
AU  - Stuart, David I.
AU  - Aguzzi, Adriano
TI  - Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region
AID  - 10.1101/2020.05.31.20118554
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.31.20118554
4099  - http://medrxiv.org/content/early/2020/08/05/2020.05.31.20118554.short
4100  - http://medrxiv.org/content/early/2020/08/05/2020.05.31.20118554.full
AB  - We describe the evolution of severe acute respiratory coronavirus 2 (SARS-CoV-2) seroprevalence in the greater area of Zurich, Switzerland, a region that has been only mildly hit by the pandemic in spite of hosting an international airport hub and a highly mobile population. Sero-prevalence studies in low-prevalence settings require large sample sizes and high-specificity methodologies. To address this particular challenge, we developed a Tripartite Automated Blood Immunoassay to assess the IgG response against three SARS-CoV-2 proteins on approximately 40’000 samples from university hospital patients and healthy blood donors. The seroprevalence increased in March 2020 (0.3%; CI95%: 0.1% - 0.5%) in the cohort of the hospital patients but rapidly plateaued in April at 1.1-1.3%, with a slight drop in June, then decreased in July to 0.3-0.7%. Seropositive samples were confirmed with Western Blotting and liquid-phase binding assays. Employing a dynamic transmission model that describes SARS-CoV-2 transmission and seroconversion in the general population of the Canton of Zurich, we estimated an infection fatality ratio of 0.6% (CI95%: 0.4%-0.8%). We conclude that a small proportion of the population in the greater area of Zurich has been exposed to SARS-CoV-2, with an IFR that is similar to that of other European areas. The evolution of seroprevalence points to a high effectiveness of containment measures and/or to rapid loss of humoral responses.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. All other authors declare no competing interests.Funding StatementInstitutional core funding by the University of Zurich and the University Hospital of Zurich to AA, as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Initiative to AA. The robotic rig was acquired with a R'Equip grant of the Swiss National Foundation to AA. Screening methodolo-gies had been developed thank to the support of an Advanced Grant of the European Research Council and a Distinguished Scientist Award of the Nomis Foundation to AA. Funding by grants of Innovation Fund of the University Hospital Zurich to AA, AvE, DS, EPM, ME, and OB. Access to the Creoptix WAVE system was kindly provided by Creoptix AG. Waedenswil, CH. Utilization of the Fluidity One-W was kindly granted by Fluidic Analytics, Cambridge, UK. This work was supported by ETH Research Grant ETH-23 18-2 and a Ph.D. fellowship by Boehringer Ingelheim Fonds to KS. Raphael Jacquat acknowledges funding by the EPSRC for Doctoral Training in Sensor Technologies and Applications (grant EP/L015889/1). ICM acknowledges funding by the Swiss Gov-ernment FCS. Carlo Cervia was funded by a Swiss Academy of Medical Sciences fellowship (#323530-191220). GFXS was supported by an COVID-19 Emergency Fund of the Director of PSI. TM is supported by Cancer Research UK grants C20724/A14414 and C20724/A26752 to Christian Siebold (Oxford). Oxford work was supported by the MRC and Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China Grant 2018-I2M-2-002. GRS is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z) and receives funding from the National Institute for Health Research Biomedical Research Centre Funding Scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kantonale Ethikkommission (KEK) ZuerichAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make ef-forts to provide microliter amounts of samples to other researchers, their availability is physically limited.